

CBL Antibody
Purified Mouse Monoclonal Antibody (Mab)
Catalog # AM8590b**Specification**

CBL Antibody - Product Information

Application	WB,E
Primary Accession	P22681
Reactivity	Human
Host	Mouse
Clonality	monoclonal
Isotype	IgG2b,k
Calculated MW	99633

CBL Antibody - Additional Information**Gene ID** 867**Other Names**

E3 ubiquitin-protein ligase CBL, 6.3.2.-, Casitas B-lineage lymphoma proto-oncogene, Proto-oncogene c-Cbl, RING finger protein 55, Signal transduction protein CBL, CBL, CBL2, RNF55

Target/Specificity

This CBL antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 450-644 amino acids from human CBL.

Dilution

WB~~1:2000

E~~Use at an assay dependent concentration.

Format

Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

CBL Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

CBL Antibody - Protein Information**Name** CBL**Synonyms** CBL2, RNF55**Function** E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways

by mediating ubiquitination of cell surface receptors (PubMed:[10514377](#), PubMed:[11896602](#), PubMed:[14661060](#), PubMed:[14739300](#), PubMed:[15190072](#), PubMed:[17509076](#), PubMed:[18374639](#), PubMed:[19689429](#), PubMed:[21596750](#), PubMed:[28381567](#)). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:[10514377](#), PubMed:[14661060](#), PubMed:[14739300](#), PubMed:[17094949](#), PubMed:[17509076](#), PubMed:[17974561](#)). Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signaling (PubMed:[15190072](#), PubMed:[18374639](#), PubMed:[21596750](#)). Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation (PubMed:[11896602](#)). Ubiquitinates EGFR and SPRY2 (PubMed:[17094949](#), PubMed:[17974561](#)). Ubiquitinates NECTIN1 following association between NECTIN1 and herpes simplex virus 1/HHV-1 envelope glycoprotein D, leading to NECTIN1 removal from cell surface (PubMed:[28381567](#)). Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis (PubMed:[15190072](#), PubMed:[18374639](#)). Essential for osteoclastic bone resorption (PubMed:[14739300](#)). The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function (PubMed:[14739300](#)). May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity).

Cellular Location

Cytoplasm. Cell membrane. Cell projection, cilium. Golgi apparatus. Note=Colocalizes with FGFR2 in lipid rafts at the cell membrane


CBL Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

CBL Antibody - Images





All lanes : Anti-CBL Antibody at 1:2000 dilution Lane 1: K562 whole cell lysate Lane 2: Jurkat whole cell lysate Lane 3: Raji whole cell lysate Lane 4: SK-BR-3 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 100 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

CBL Antibody - Background

Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3.

CBL Antibody - References

- Blake T.J.,et al.Oncogene 6:653-657(1991).
- Taylor T.D.,et al.Nature 440:497-500(2006).
- Howlett C.J.,et al.Biochem. Biophys. Res. Commun. 257:129-138(1999).
- Joazeiro C.A.,et al.Science 286:309-312(1999).
- Donovan J.A.,et al.J. Biol. Chem. 269:22921-22924(1994).